Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Antiplatelet agents, like aspirin, may reduce liver fibrosis by inhibiting platelet activation and growth factor production.
• Previous studies suggested a link between aspirin use and reduced liver fibrosis, warranting further investigation.
• The Aspirin-Myocardial Infarction Study (AMIS) provides a unique dataset to explore this association in a rigorous trial setting.

Purpose of the Study:

• To investigate the effect of daily high-dose aspirin on liver fibrosis markers in patients with a history of myocardial infarction.
• To determine if aspirin use influences the aspartate aminotransferase (AST)-to-Platelet Ratio Index (APRI), a surrogate for liver fibrosis.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial (AMIS) involving 4,524 participants.
• APRI was calculated at baseline and annually using platelet count and AST levels.
• Statistical analysis assessed the annual change in APRI associated with daily aspirin use.

Main Results:

• Daily aspirin use was associated with a slight, non-significant increase in APRI (0.007 per year).
• Aspirin did not significantly impact platelet counts.
• In a subgroup with probable significant fibrosis, aspirin showed a non-significant trend towards APRI reduction.

Conclusions:

• High-dose aspirin did not significantly affect APRI in patients with myocardial infarction.
• The findings do not support the use of daily high-dose aspirin for reducing liver fibrosis in this population.
• New clinical trials are necessary to evaluate other antiplatelet agents or aspirin regimens for potential antifibrotic effects.